Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasia

References

• Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W, Begaud B, et al.; Triumph Pan European Expert Panel. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care–the Triumph project. Eur Urol 2002;42:323–328.
   PubMed Web of Science ®Google Scholar
• Lai MK. Recent advances in the treatment of benign prostatic hyperplasia. J Formos Med Assoc 1996;95:822–827.
   Google Scholar
• Artibani W. Introduction. Eur Urol 2001;40 Suppl 4:1–4.
   Google Scholar
• Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147 Suppl 2:S88–119.
   PubMed Web of Science ®Google Scholar
• Emberton M, Cornel EB, Bassi PF, Fourcade RO, Gómez JM, Castro R. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract 2008;62:1076–1086.
   PubMed Web of Science ®Google Scholar
• Peters TJ, Donovan JL, Kay HE, Abrams P, de la Rosette JJ, Porru D, Thüroff JW. The International Continence Society “Benign Prostatic Hyperplasia” Study: the botherosomeness of urinary symptoms. J Urol 1997;157:885–889.
   PubMed Web of Science ®Google Scholar
• Scarpa RM. Lower urinary tract symptoms: what are the implications for the patients? Eur Urol 2001;40 Suppl 4:12–20.
   PubMedGoogle Scholar
• AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia. J Urol 2003;170:530.
   Google Scholar
• Franco-Salina G, de la Rosette JJ, Michel MC. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and controlled absorption system formulations. Clinical Pharmacokinetics 2010; 49:177.
   Google Scholar
• Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081–1088.
   PubMed Web of Science ®Google Scholar
• Badgujar BP, Mundada AS. The technologies used for developing orally disintegrating tablets: a review. Acta Pharm 2011;61:117–139.
   PubMed Web of Science ®Google Scholar
• International Prostate Symptom Score (I-PSS). Urological Sciences Research Foundation. http://www.usrf.org/questionnaires/AUA_SymptomScore.html.
   Google Scholar
• Meyhoff HH, Hald T, Nordling J, Andersen JT, Bilde T, Walter S. A new patient weighted symptom score system (DAN-PSS-1). Clinical assessment of indications and outcomes of transurethral prostatectomy for uncomplicated benign prostatic hyperplasia. Scand J Urol Nephrol 1993;27:493–499.
   PubMed Web of Science ®Google Scholar
• Hansen BJ, Flyger H, Brasso K, Schou J, Nordling J, Thorup Andersen J, Mortensen S, et al. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol 1995;76:451–458.
   PubMedGoogle Scholar
• Li NC, Chen S, Yang XH, Du LD, Wang JY, Na YQ; and The Beijing Tamsulosin Study Group. Efficacy of low-dose tamsulosin in chinese patients with symptomatic benign prostatic hyperplasia. Clin Drug Investig 2003;23:781–787.
   PubMed Web of Science ®Google Scholar
• Lee HS, Kim SW, Oh SJ, Choo MS, Lee KS. Efficacy and safety of tamsulosin for treating lower urinary tract symptoms associated with benign prostatic hyperplasia: a multicenter, randomized, controlled, open-label non-inferiority study. Korean J Urol 2012;53:178–183.
   PubMedGoogle Scholar
• Kojima Y, Sasaki S, Imura M, Kubota Y, Hayashi Y, Kohri K. Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria: a prospective open-label long-term study using frequency-volume chart. Neurourol Urodyn 2012;31:80–85.
   Google Scholar
• Cohen SA, Parsons JK. Combination pharmacological therapies for the management of benign prostatic hyperplasia. Drugs Aging 2012;29:275–284.
   Google Scholar
• Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008;5:2170–2178.
   PubMed Web of Science ®Google Scholar
• Gacci M, Vittori G, Tosi N, Siena G, Rossetti MA, Lapini A, Vignozzi L, et al. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 2012;9:1624–1633.
   PubMed Web of Science ®Google Scholar
• Barendrecht MM, Koopmans RP, de la Rosette JJ, Michel MC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int 2005; 95(Suppl 4):S19–S28.
   Google Scholar
• Michel MC. Alpha1-adrenoceptors and ejaculatory function. Br J Pharmacol 2007;152:289–290.
   PubMed Web of Science ®Google Scholar
• Hisasue S, Furuya R, Itoh N, Kobayashi K, Furuya S, Tsukamoto T. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol 2006;13:1311–1316.
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 2006;176:1529–1533.
   PubMed Web of Science ®Google Scholar
• Goktas S, Kibar Y, Kilic S, Topac H, Coban H, Seckin B. Recovery of abnormal ejaculation by intermittent tamsulosin treatment. J Urol 2006;175:650–2; discussion 652.
   PubMed Web of Science ®Google Scholar